指南与共识心脑血管急症创伤与烧伤

S100B 作为急诊头部外伤患者颅内病变排除试验的诊断性能:符合 NICE 头部外伤指南 CT 指征的人群

Diagnostic performance of S100B as a rule-out test for intracranial pathology in head-injured patients presenting to the emergency department who meet NICE Head Injury Guideline criteria for CT-head scan.
指南 / 共识 · Emerg Med J · 2022-11-02
一句话结论符合 NICE CT 指征的头部外伤患者,伤后 6 小时内 S100B 阴性排除颅内病变的 NPV 为 97.3%,理论上可减少约四分之一 CT 检查。

这项多中心前瞻性观察研究纳入 2020 年 5 月至 2021 年 6 月急诊就诊、符合 NICE 头部外伤指南 CT 指征的成人头部外伤患者 265 例,其中 35 例(13.2%)CT 发现颅内病变。以 Cobas Elecsys-S100 检测血清 S100B,阈值 >0.1 µg/mL 为阳性。伤后 6 小时内检测的敏感度为 93.8%(95%CI 69.8%~99.8%),特异度 30.8%(95%CI 22.6%~40.0%),NPV 97.3%(95%CI 84.2%~99.6%),AUC 0.73(95%CI 0.61~0.85;p=0.003)。作者认为伤后 6 小时内 S100B 在低风险头部外伤患者中排除显著颅内病变表现良好,理论上与 NICE 指南联用可使 CT 检查率降低约四分之一,漏诊率 <1%。

要点

  • 伤后 6 小时内 S100B 的 NPV 为 97.3%(95%CI 84.2%~99.6%),敏感度 93.8%(95%CI 69.8%~99.8%),特异度 30.8%(95%CI 22.6%~40.0%)。
  • 伤后 24 小时内 S100B 的敏感度降至 82.9%(95%CI 66.4%~93.44%),NPV 94.29%(95%CI 88.7%~97.2%),AUC 0.65(95%CI 0.56~0.74;p=0.046)。
  • 理论上以 S100B 排除颅内病变,伤后 6 小时内可减少 27.1%(95%CI 18.9%~36.8%)的 CT 检查,漏诊显著损伤风险 0.75%(95%CI 0.0%~2.2%)。
  • 理论上伤后 24 小时内可减少 37.4%(95%CI 32.0%~47.2%)的 CT 检查,漏诊显著损伤风险 2.3%(95%CI 0.5%~4.1%)。
  • 本研究为多中心前瞻性观察研究,S100B 阈值 >0.1 µg/mL 为阳性,适用于符合 NICE 头部外伤指南 CT 指征的成人患者。

适用人群与场景

  • 2020 年 5 月至 2021 年 6 月急诊就诊、符合 NICE 头部外伤指南 CT 指征的成人头部外伤患者,共纳入 265 例。
  • 研究对象为低风险患者(作者结论中描述为 low-risk patients presenting with head injury)。

诊断标准与关键阈值

  • 采用 NICE 头部外伤指南(NICE HIG)CT 指征作为入组条件。
  • S100B 检测阈值 >0.1 µg/mL 定义为阳性。
  • 以放射科值班医师报告的 CT 头部扫描颅内病变为参考标准。

处置流程与药物剂量

  • 采集静脉血样,使用 Cobas Elecsys-S100 模块检测血清 S100B。
  • 伤后 6 小时内检测 S100B,若阴性(≤0.1 µg/mL)可辅助排除显著颅内病变,理论上可减少 27.1% 的 CT 检查。
  • 伤后 24 小时内检测 S100B,阴性时理论上可减少 37.4% 的 CT 检查,但漏诊显著损伤风险为 2.3%。

红旗征与不能漏的情况

  • 伤后 24 小时内 S100B 排除策略的漏诊显著损伤风险为 2.3%(95%CI 0.5%~4.1%),高于 6 小时内的 0.75%。
  • 伤后 24 小时内 S100B 敏感度为 82.9%,低于 6 小时内的 93.8%。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察研究;样本量 265 例,颅内病变阳性 35 例(13.2%)。
  • 伤后 6 小时内 S100B:敏感度 93.8%(95%CI 69.8%~99.8%),特异度 30.8%(95%CI 22.6%~40.0%),NPV 97.3%(95%CI 84.2%~99.6%),AUC 0.73(95%CI 0.61~0.85;p=0.003)。
  • 伤后 24 小时内 S100B:敏感度 82.9%(95%CI 66.4%~93.44%),特异度 43.0%(95%CI 36.6%~49.7%),NPV 94.29%(95%CI 88.7%~97.2%),AUC 0.65(95%CI 0.56~0.74;p=0.046)。
  • 理论上减少 CT 检查:伤后 6 小时内 27.1%(95%CI 18.9%~36.8%),伤后 24 小时内 37.4%(95%CI 32.0%~47.2%);漏诊显著损伤风险分别为 0.75%(95%CI 0.0%~2.2%)和 2.3%(95%CI 0.5%~4.1%)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,伤后 6 小时内 S100B 在低风险头部外伤患者中排除显著颅内病变表现良好。
  • 作者认为,若在 NICE 指南基础上加用 S100B,理论上 CT 检查率可降低约四分之一,漏诊率 <1%。

指南或共识出处

  • National Institute of Health and Clinical Excellence Head Injury Guideline (NICE HIG)

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury is a common ED presentation. CT-head utilisation is escalating, exacerbating resource pressure in the ED. The biomarker S100B could assist clinicians with CT-head decisions by excluding intracranial pathology. Diagnostic performance of S100B was assessed in patients meeting National Institute of Health and Clinical Excellence Head Injury Guideline (NICE HIG) criteria for CT-head within 6 and 24 hours of injury.

METHODS: This multicentre prospective observational study included adult patients presenting to the ED with head injuries between May 2020 and June 2021. Informed consent was obtained from patients meeting NICE HIG CT-head criteria. A venous blood sample was collected and serum was tested for S100B using a Cobas Elecsys-S100 module; >0.1 µg/mL was the threshold used to indicate a positive test. Intracranial pathology reported on CT-head scan by the duty radiologist was used as the reference standard to review diagnostic performance.

RESULTS: This study included 265 patients of whom 35 (13.2%) had positive CT-head findings. Within 6 hours of injury, sensitivity of S100B was 93.8% (95% CI 69.8% to 99.8%) and specificity was 30.8% (22.6% to 40.0%). Negative predictive value (NPV) was 97.3% (95% CI 84.2% to 99.6%) and area under the curve (AUC) was 0.73 (95% CI 0.61 to 0.85; p=0.003). Within 24 hours of injury, sensitivity was 82.9% (95% CI 66.4% to 93.44%) and specificity was 43.0% (95% CI 36.6% to 49.7%). NPV was 94.29% (95% CI 88.7% to 97.2%) and AUC was 0.65 (95% CI 0.56 to 0.74; p=0.046). Theoretically, use of S100B as a rule-out test would have reduced CT-head scans by 27.1% (95% CI 18.9% to 36.8%) within 6 hours and 37.4% (95% CI 32.0% to 47.2%) within 24 hours. The risk of missing a significant injury with this approach would have been 0.75% (95% CI 0.0% to 2.2%) within 6 hours and 2.3% (95% CI 0.5% to 4.1%) within 24 hours.

CONCLUSION: Within 6 hours of injury, S100B performed well as a diagnostic test to exclude significant intracranial pathology in low-risk patients presenting with head injury. In theory, if used in addition to NICE HIGs, CT-head rates could reduce by one-quarter with a potential miss rate of <1%.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Rogan A, Sik A, Dickinson E, et al. Diagnostic performance of S100B as a rule-out test for intracranial pathology in head-injured patients presenting to the emergency department who meet NICE Head Injury Guideline criteria for CT-head scan. Emerg Med J. 2022. PMID: 36323496. doi:10.1136/emermed-2022-212549

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。